Across 3 days of the Neoantigen Summit Europe, you will meet 100+ experts focused in advancing neoantigen targeting, ensuring you meet the right people and have valuable conversations in intimate settings of workshops, roundtables and networking sessions.

With an exclusively case-study led agenda, this year’s meeting will focus on:

• Successfully eliciting potent immune response to neoantigens
• Understanding the regulatory requirements in the clinical development of neoantigen based therapies
• The most up-to-date clinical experiences of neoantigen personalised cancer immunotherapy

Why you should attend the Neoantigen Summit Europe:

• Gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy this year.
• Delve into novel approaches for more effective neoantigen identification with AbbVie, Vall d’Hebron Institute of Oncology & Genentech
• Learn how pioneering companies are developing novel methods to weaponise neoantigens including biospecific antibodies, oncolotic viruses and self-assembling nanoparticles with Gritstone Oncology, Avidea and Valo Therapeutics
• Evaluate different techniques of measuring immunogeneity with Precision Biologics and Vaxon Biotech
• Address important clinical trial design, regulatory and manufacturing considerations for both personalised neoantigen vaccines and cell-based therapy with Genocea, MHRA and Washington University School of Medicine
• Identify different techniques in designing offthe-shelf, shared neoantigen-based personalised vaccines with Treos Bio, Calviri and Frame Cancer Therapeutics